{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:04:20Z","timestamp":1784646260265,"version":"3.55.0"},"reference-count":15,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Nucl. Med.\n                Technol."],"accepted":{"date-parts":[[2026,6,17]]},"DOI":"10.2967\/jnmt.126.272466","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:50:06Z","timestamp":1784645406000},"page":"jnmt.126.272466","source":"Crossref","is-referenced-by-count":0,"title":["Current Status of Clinical\n                    <sup>177<\/sup>\n                    Lu-PSMA Radiopharmaceutical Therapies: Insights from a Survey of High-End Nuclear Medicine Theranostic Centers"],"prefix":"10.2967","author":[{"given":"Mehdi","family":"Djekidel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Dominguez-Konicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.H.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholam (Reza)","family":"Berenji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026072107251139000_jnmt.126.272466v1.1","unstructured":"Novartis Pluvicto approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer. Novartis website. https:\/\/www.novartis.com\/news\/media-releases\/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. Published March 23, 2022. Accessed June 30, 2026."},{"key":"2026072107251139000_jnmt.126.272466v1.2","unstructured":"FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Published March 28, 2025. Accessed June 30, 2026."},{"key":"2026072107251139000_jnmt.126.272466v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"2026072107251139000_jnmt.126.272466v1.4","unstructured":"PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer. Novartis website. https:\/\/www.novartis.com\/news\/media-releases\/psmaddition-data-show-novartis-pluvictotm-delays-progression-end-stage-prostate-cancer. Published October 19, 2025. Accessed June 30, 2026."},{"key":"2026072107251139000_jnmt.126.272466v1.5","unstructured":"Neoadjuvant Lu-177-PSMA-617 in patients with high risk localized prostate cancer undergoing radical prostatectomy (ClinicalTrials.gov ID NCT06798558). National Library of Medicine website. https:\/\/clinicaltrials.gov\/study\/NCT06798558. Accessed June 30, 2026."},{"key":"2026072107251139000_jnmt.126.272466v1.6","doi-asserted-by":"crossref","unstructured":"Hennes D Sayyid RK . EAU 2026: biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu]Lu-PSMA-617 prior to prostatectomy: follow-up of the LuTectomy trial. https:\/\/www.urotoday.com\/conference-highlights\/eau-2026\/eau-2026-prostate-cancer\/167403-eau-2026-biochemical-recurrence-and-safety-in-patients-with-high-risk-localised-prostate-cancer-treated-with-177lu-lu-psma-617-prior-to-prostatectomy-follow-up-of-the-lutectomy-trial.html. Accessed June 30, 2026.","DOI":"10.1016\/S0302-2838(26)01246-7"},{"key":"2026072107251139000_jnmt.126.272466v1.7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(25)00762-4","article-title":"[177Lu]-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study","volume":"27","author":"Priv\u00e9","year":"2026","journal-title":"Lancet Oncol."},{"key":"2026072107251139000_jnmt.126.272466v1.8","unstructured":"PSMA therapy delays hormone therapy in prostate cancer. Radboud University Medical Center website. https:\/\/www.radboudumc.nl\/en\/news-items\/2026\/psma-therapie-stelt-hormoontherapie-bij-prostaatkanker-uit. Published March 31, 2026. Accessed April 9, 2026."},{"key":"2026072107251139000_jnmt.126.272466v1.9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1470-2045(26)00017-3","article-title":"[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b\/2 study","volume":"27","author":"Sandhu","year":"2026","journal-title":"Lancet Oncol."},{"key":"2026072107251139000_jnmt.126.272466v1.10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026072107251139000_jnmt.126.272466v1.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269424"},{"key":"2026072107251139000_jnmt.126.272466v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270011"},{"key":"2026072107251139000_jnmt.126.272466v1.13","unstructured":"Average survey response rate in 2025: benchmarks, drivers, and CX implications. Clootrack website. https:\/\/www.clootrack.com\/knowledge\/survey-response-rate\/average-survey-response-rate-in-2025-benchmarks-drivers-and-cx-implications. Published October 13, 2025. Accessed June 30, 2026."},{"key":"2026072107251139000_jnmt.126.272466v1.14","unstructured":"What\u2019s the industry standard for survey response rate & how UGC can improve yours. Skeepers website. https:\/\/skeepers.io\/blog\/whats-the-industry-standard-for-survey-response-rate-how-ugc-can-improve-yours\/. Published March 26, 2025. Accessed June 30, 2026."},{"key":"2026072107251139000_jnmt.126.272466v1.15","unstructured":"Radiopharmaceutical Therapy Registry (RaPTR). Society of Nuclear Medicine and Molecular Imaging website. https:\/\/snmmi.org\/Web\/Clinical-Practice\/RaPTR\/Default.aspx. Accessed June 30, 2026."}],"container-title":["Journal of Nuclear Medicine Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnmt.126.272466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:50:10Z","timestamp":1784645410000},"score":1,"resource":{"primary":{"URL":"http:\/\/tech.snmjournals.org\/lookup\/doi\/10.2967\/jnmt.126.272466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":15,"alternative-id":["10.2967\/jnmt.126.272466"],"URL":"https:\/\/doi.org\/10.2967\/jnmt.126.272466","relation":{},"ISSN":["0091-4916","1535-5675"],"issn-type":[{"value":"0091-4916","type":"print"},{"value":"1535-5675","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}